Rose (AIM: ROSE), the AIM quoted natural resources business, is pleased to provide an update on the potential disposal of the Company’s mineral processing mill operation in San Dieguito de Arriba, State of Nayarit, Mexico and its associated assets, licenses and agreements (together, the “SDA Mill”) to Magellan Gold Corporation (OTCQB:MAGE) (“Magellan”), as announced on 6 March 2017.
SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that, as envisaged in the Company’s Admission Document dated 29 March 2017, it has agreed an eight month extension to its research contract with the University of Manchester to June 2018. This contract extension includes provision for the appointment of a second technician to the Company. This will increase the Company’s ability to develop its SkinBiotix® platform.
N4 Pharma Plc (AIM: N4P), a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, is pleased to announce the readmission today of the Company’s ordinary shares to trading on AIM and the commencement of dealings in the New Ordinary Shares under the ticker N4P (“Admission”).
Share Talk took the opportunity to speak with N4 Pharma’s Founder and CEO Nigel Theobald following their admission and first day of shares being available for dealing on AIM .
Diversified Gas & Oil PLC (AIM: DGOC), a US based gas and oil producer, is pleased to confirm the closing of the acquisition of the package of 1,300 producing oil and gas wells in the states of Ohio and Pennsylvania (the “Acquisition”), initially announced on 24 February 2017.
SkinBioTherapeutics plc (AIM: SBTX, the “Company”), a life science company focused on skin health, announces the commencement of dealings in its Ordinary Shares on AIM 5 March 2017 under the ticker code SBTX and the ISIN number: GB00BF33H870.
Share Talk spoke to Declan Service, CEO of Integumen Plc about today’s IPO to the FTSE AIM market after a fundraise of £2.25M.